Development of an automated capillary nano-immunoassay—Simple Western assay—to quantify total TDP43 protein in human platelet samples
Frontotemporal lobar degeneration syndrome is the second cause of young-onset dementia. Unfortunately, reliable biomarkers are currently lacking for the diagnosis of this disease. As TDP43 protein is one of the proteins pathologically involved in frontotemporal lobar degeneration, many studies have been performed to assess TDP43 protein diagnostic performances. Mixed results were obtained using cerebrospinal fluid and plasma samples so far. The aim of the study was to develop an automated capillary nano-immunoassay—Simple Western assay—to detect and quantify TDP43 protein simultaneously in human blood-based samples. Simple Western assay was developed with two different cell lysates used as positive controls and was compared to Western blot. TDP43 protein profiles in plasma samples were disappointing, as they were discordant to our positive controls. On the contrary, similar TDP43 patterns were obtained between platelet samples and cell lysates using both assays. Simple Western assay provided good quantitative performances in platelet samples: a linearity of signals could be observed (r2 = 0.994), associated to a within-run variability at 5.7%. Preliminary results based on a cohort of patients suffering from frontotemporal lobar degeneration showed large inter-individual variations superior to Simple Western’s analytical variability. Simple Western assay seems to be suitable for detecting and quantifying TDP43 protein in platelet samples, providing a potential candidate biomarker in this disease. Further confirmation studies should now be performed on larger cohorts of patients to assess diagnostic performances of TDP43 protein in platelet samples.
KeywordsDementia TDP43 proteinopathies Capillary electrophoresis/electrophoresis High-throughput screening assays Biomarkers
Compliance with ethical standards
Conflict of interest
Ingolf Lachmann provided 2G10 antibody and reports that he is employee of AJ Roboscreen GmbH®, Leipzig, Germany. No other conflict of interest is reported.
This study was based on biological samples collected for routine diagnosis in the framework of a medical follow-up recommended for FTLD patients. The samples associated to written consents were stored in a bio bank with the authorization from the French Ministry of Health (Declaration Number DC-2008-304). Authorization for handling personal data was granted by the French data protection commission [Commission Nationale de l’Informatique et des Libertés (CNIL)].
The patients included in this study or their legal next of kin gave two informed written consents: the first one for FTLD genetic testing and the second one authorizing a change of biological purpose for remaining parts of samples.
- 9.Gao J, Wang L, Huntley ML, Perry G, Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem. 2018. https://doi.org/10.1111/jnc.14327.
- 11.Geser F, Prvulovic D, O'Dwyer L, Hardiman O, Bede P, Bokde AL, et al. On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol. 2011;95(4):649–62. https://doi.org/10.1016/j.pneurobio.2011.08.011.CrossRefPubMedPubMedCentralGoogle Scholar
- 12.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263–9. https://doi.org/10.1016/j.jalz.2011.03.005.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Foulds PG, Davidson Y, Mishra M, Hobson DJ, Humphreys KM, Taylor M, et al. Plasma phosphorylated-TDP-43 protein levels correlate with brain pathology in frontotemporal lobar degeneration. Acta Neuropathol. 2009;118(5):647–58. https://doi.org/10.1007/s00401-009-0594-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018. https://doi.org/10.1007/s12035-018-0947-6.
- 23.Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, Lumbroso S, et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet. 2014;51(6):419–24. https://doi.org/10.1136/jmedgenet-2014-102360.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Goossens J, Vanmechelen E, Trojanowski JQ, Lee VM, Van Broeckhoven C, van der Zee J, et al. TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies. Acta Neuropathol Commun. 2015;3:15. https://doi.org/10.1186/s40478-015-0195-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Nelson GM, Guynn JM, Chorley BN. Procedure and key optimization strategies for an automated capillary electrophoretic-based immunoassay method. J Vis Exp. 2017;(127). https://doi.org/10.3791/55911.
- 28.R&D systems a biotechne brand. Human/Mouse/Rat TDP-43/TARDBP Antibody - Monoclonal Mouse IgG2A Clone # 671834 - Catalog Number: MAB7778 - https://resources.rndsystems.com/pdfs/datasheets/mab7778.pdf. Rev. 2/7/2018.
- 29.Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CA, Lehnert S, et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008;65(11):1481–7. https://doi.org/10.1001/archneur.65.11.1481.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Fourier A, Dorey A, Perret-Liaudet A, Quadrio I. Detection of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease patients using a new automated capillary Western assay. Mol Neurobiol. 2017. https://doi.org/10.1007/s12035-017-0607-2.